ALC
ALCON INC
$66.11
-1.05%
$33.9B
No data for this timeframe.
Vol
Market Cap$33.9B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (83%)
Congressional1 trades
Recent Activity
Jun 2, 2026
short_volume
Short Volume: ALC — 66.6% short (0.5M / 0.8M)
Short: 501,554 | Exempt: 64,516 | TRF Vol: 753,554 | Short Ratio: 66.6% | Off-exchange volume (dark
May 6, 2026
Event
GenTeal Tears, Lubricant Eye Gel, Sterile, 10g (0.34 Fl oz), Distributed by: Alcon Laboratories, Inc., Fort Worth, Texas 76134, USA, NDC: 0065-8064-01.
Class II: Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may im
Mar 12, 2026
Congress
Josh Gottheimer sell
$1,001 - $15,000 — House
Price Targets
$88.52
+30.4% upside
Strong Buy
Current $67.90
Low $66.00
Median $88.00
High $112.00
15 analysts
$66.00
$112.00
Analyst Ratings
4Strong Buy
11Buy
2Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 8, 2026 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
| May 7, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 7, 2026 | Baird | MAINTAIN | Outperform → Outperform |
| May 6, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.75 ▼ -0.9% | $0.66 — $0.79 | -1% YoY | 14 |
| Next Q | $0.56 | $0.45 — $0.64 | 16% YoY | 8 |
| Current FY | $3.47 | $3.36 — $3.57 | 13% YoY | 25 |
| Next FY | $3.97 | $3.78 — $4.25 | 15% YoY | 25 |
Congressional Trades
1 members: 0 buys, 1 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Josh Gottheimer | D | SELL | $1,001 - $15,000 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (83% buy). Based on 18 analysts: 4 strong buy, 11 buy, 2 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$88.52 mean target
+30.4% upside
Strong Buy (1.54)
$66.00 Low
$112.00 High
| Metric | Value |
|---|---|
| Current Price | $67.90 |
| Target Low | $66.00 |
| Target Mean | $88.52 |
| Target Median | $88.00 |
| Target High | $112.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.54) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.75 | $0.66 | $0.79 | -0.8% | -0.9% | 3↑ 9↓ | $2.8B | 6.8% | 14 |
| Next Q 2026-09-30 |
$0.56 | $0.45 | $0.64 | 16.4% | +0.0% | 3↑ 3↓ | $2.8B | 5.9% | 8 |
| Current FY 2026-12-31 |
$3.47 | $3.36 | $3.57 | 12.9% | — | 17↑ 2↓ | $11.1B | 7.0% | 25 |
| Next FY 2027-12-31 |
$3.97 | $3.78 | $4.25 | 14.5% | — | 15↑ 4↓ | $11.8B | 6.3% | 25 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.754 | |
| 7d ago | $0.754 | |
| 30d ago | $0.760 | -0.006 |
| 60d ago | $0.796 | -0.042 |
| 90d ago | $0.799 | -0.045 |
7 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 8, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| May 7, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| May 6, 2026 | Needham | MAINTAIN | Buy | Buy |
| May 6, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 9, 2026 | Stifel | MAINTAIN | Hold | Hold |
| Feb 26, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 26, 2026 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
| Feb 26, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Stifel | DOWNGRADE | Buy | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 11 | 2 | 1 | 0 | 83% | |
| May 1, 2026 | 4 | 11 | 2 | 3 | 0 | 75% | |
| Apr 1, 2026 | 4 | 11 | 2 | 3 | 0 | 75% | |
| Mar 1, 2026 | 4 | 12 | 2 | 2 | 0 | 80% | |
| Feb 1, 2026 | 3 | 12 | 3 | 2 | 0 | 75% | |
| Jan 1, 2026 | 3 | 10 | 4 | 2 | 0 | 68% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 0 buys, 1 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | Josh Gottheimer | D | HOUSE | SELL | $1,001 - $15,000 | Alcon Inc | Apr 9, 2026 (29d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
short_volume
Short Volume: ALC — 66.6% short (0.5M / 0.8M)
Short: 501,554 | Exempt: 64,516 | TRF Vol: 753,554 | Short Ratio: 66.6% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: ALC — 58.0% short (0.5M / 0.8M)
Short: 455,551 | Exempt: 1,108 | TRF Vol: 786,097 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: ALC — 71.0% short (0.6M / 0.8M)
Short: 600,007 | Exempt: 2,489 | TRF Vol: 845,477 | Short Ratio: 71.0% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: ALC — 59.0% short (0.6M / 1.1M)
Short: 628,442 | Exempt: 839 | TRF Vol: 1,064,707 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: ALC — 60.7% short (0.6M / 1.0M)
Short: 601,587 | Exempt: 81 | TRF Vol: 991,684 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: ALC — 70.4% short (0.7M / 1.0M)
Short: 703,682 | Exempt: 9,642 | TRF Vol: 999,214 | Short Ratio: 70.4% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: ALC — 80.5% short (0.9M / 1.1M)
Short: 863,547 | Exempt: 1,280 | TRF Vol: 1,072,463 | Short Ratio: 80.5% | Off-exchange volume (dark pool + OTC)
May 21, 2026
Clinical Trial
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
Phase Phase 3 — COMPLETED
May 21, 2026
clinical_trial_readout
Results Pending: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution (Phase 3) — Completed 45d ago
Trial: Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
Sponsor: Alcon Research
Phase: Phase 3 | Completed: 2026-04-06
Condit
May 21, 2026
short_volume
Short Volume: ALC — 62.8% short (0.7M / 1.1M)
Short: 694,852 | Exempt: 84 | TRF Vol: 1,106,313 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: ALC — 57.8% short (0.4M / 0.8M)
Short: 438,446 | Exempt: 0 | TRF Vol: 758,582 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: ALC — 55.3% short (0.3M / 0.6M)
Short: 335,961 | Exempt: 0 | TRF Vol: 607,883 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: ALC — 43,943 shares ($2.8M) failed to deliver
Settlement: 20260513, Price: $63.78, FTD Value: $2,802,684.54, ALCON INC. ORDINARY SHARES (CH
May 12, 2026
short_volume
Short Volume: ALC — 56.9% short (0.5M / 0.9M)
Short: 499,083 | Exempt: 0 | TRF Vol: 877,750 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: ALC — 67.1% short (0.9M / 1.4M)
Short: 917,057 | Exempt: 5 | TRF Vol: 1,366,211 | Short Ratio: 67.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_interest
FTD: ALC — 18,048 shares ($1.1M) failed to deliver
Settlement: 20260511, Price: $62.56, FTD Value: $1,129,082.88, ALCON INC. ORDINARY SHARES (CH
May 6, 2026
FDA
GenTeal Tears, Lubricant Eye Gel, Sterile, 10g (0.34 Fl oz), Distributed by: Alcon Laboratories, Inc., Fort Worth, Texas 76134, USA, NDC: 0065-8064-01.
Class II: Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.
May 6, 2026
FDA
Systane, Lubricant Eye Gel, Night Gel, Sterile, 10g (0.35 oz), Processed in France for: Alcon Laboratiroes, Inc., Fort Worth, TX 76134, USA, NDC 0065-0474-01
Class II: Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.
Apr 1, 2026
Clinical Trial
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
Phase Phase 3 — COMPLETED